Heart Failure and Transplant Unit, La Fe University and Polytechnic Hospital, Valencia, Spain; Department of Cardiology, La Fe University and Polytechnic Hospital, Valencia, Spain.
Heart Failure and Transplant Unit, La Fe University and Polytechnic Hospital, Valencia, Spain; Department of Cardiology, La Fe University and Polytechnic Hospital, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Transplant Proc. 2021 Nov;53(9):2739-2742. doi: 10.1016/j.transproceed.2021.08.040. Epub 2021 Sep 30.
The purpose of the study was to analyze postcardiac transplant complications in patients who received transplants with short-term mechanical ventricular assist devices and to compare complications according to the type of device.
Ambispective and consecutive study of urgent heart transplants from 2015 to 2019. Pediatric transplants, retransplants, and combined transplants were excluded. A total of 45 patients were analyzed in 4 groups: (1) venoarterial extracorporeal membrane oxygenation (ECMO) implanted <10 days before heart transplant (HTx) (n = 17); (2) ECMO implanted for more than 10 days (n = 8); (3) Levitronix Centrimag implanted in INTERMACS 2 to 3 patients (n = 13); and (4) Levitronix Centrimag implanted in INTERMACS 2 patients (n = 7). ECMO assistance was in INTERMACS 2 and severe right ventricular dysfunction. Levitronix Centrimag was implanted in patients with preserved right ventricular function.
Primary graft failure associated with the need for ECMO was more frequent in patients with ECMO than with Levitronix (P < .05). When comparing the 2 groups with ECMO, an implant more than 10 days before HTx was associated, after transplant, with a longer stay in the critical care unit (P = .02), higher mortality (P = .03), and an increase in complications in general. When comparing the 2 groups with Levitronix, all the parameters studied were much better when the Levitronix was implanted in INTERMACS 2-3 (P < .05). On the other hand, all cases of deep vein thrombosis and pulmonary thromboembolism occurred in patients who were assisted with ECMO.
HTx with mechanical assist devices is associated with significant complications. ECMO produces more complications than the Levitronix Centrimag, although they are related to the days of implantation. The best group are patients implanted with a Levitronix in INTERMACS 2-3.
本研究的目的是分析接受短期机械心室辅助装置移植的患者心脏移植后的并发症,并根据装置类型比较并发症。
对 2015 年至 2019 年期间紧急心脏移植患者进行前瞻性和连续性研究。排除儿科移植、再次移植和联合移植。共分析了 45 例患者分为 4 组:(1)静脉动脉体外膜肺氧合(ECMO)植入心脏移植(HTx)前<10 天(n=17);(2)植入超过 10 天的 ECMO(n=8);(3)Levitronix Centrimag 植入 INTERMACS 2 至 3 级患者(n=13);和(4)Levitronix Centrimag 植入 INTERMACS 2 级患者(n=7)。ECMO 辅助治疗适用于 INTERMACS 2 级和严重右心功能不全患者。Levitronix Centrimag 植入右心功能保留的患者。
与 Levitronix 相比,ECMO 患者的原发性移植物衰竭伴 ECMO 需求更为常见(P<0.05)。当比较 2 组 ECMO 时,移植前 10 天以上植入与 ICU 停留时间延长(P=0.02)、死亡率升高(P=0.03)以及并发症增加有关。当比较 2 组 Levitronix 时,当 Levitronix 植入 INTERMACS 2-3 时,所有研究参数均更好(P<0.05)。另一方面,所有深静脉血栓形成和肺血栓栓塞病例均发生在接受 ECMO 辅助治疗的患者中。
心脏移植机械辅助装置与严重并发症相关。ECMO 比 Levitronix Centrimag 产生更多并发症,尽管这些并发症与植入天数有关。最好的是植入 INTERMACS 2-3 的 Levitronix 的患者。